<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04042116</url>
  </required_header>
  <id_info>
    <org_study_id>CO-3810-101</org_study_id>
    <secondary_id>ENGOT-GYN3/AGO/LIO</secondary_id>
    <nct_id>NCT04042116</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor</brief_title>
  <official_title>LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Gynaecological Oncological Trial Groups (ENGOT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clovis Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in&#xD;
      combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by&#xD;
      evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced&#xD;
      gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed&#xD;
      state (Food Effect)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the recommended Phase 2 dose of the combination of lucitanib and nivolumab (Phase 1b)</measure>
    <time_frame>First dose of study drug through at least 100 days after end of treatment (up to approximately 2 years)</time_frame>
    <description>Incidence of adverse events and clinical lab abnormalities defined as dose-limiting toxicities and maximum tolerated dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Overall Response Rate (Phase 2)</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Confirmed best overall response (PR or CR) based on investigator assessment of objective response according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and long-term safety and tolerability of the combination (Phase 2)</measure>
    <time_frame>From first dose of study drug until disease progression (up to approximately 2 years)</time_frame>
    <description>Incidence of AEs, clinical lab abnormalities, and dose modifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further evaluation of preliminary efficacy of combination (Phase 2)</measure>
    <time_frame>From first dose of study drug until at least 100 days after end of treatment (up to approximately 2 years)</time_frame>
    <description>Duration of response, progression-free survival, and disease control per RECIST v1.1, overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]</measure>
    <time_frame>From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Area under the curve [AUCss]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]</measure>
    <time_frame>From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Maximum plasma concentration [Cmax,ss]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect]</measure>
    <time_frame>From first dose of study drug to the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Total clearance of drug after oral administration [CLss/F]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at Steady State [Phase 1 dose escalation and Food Effect, Phase 2]</measure>
    <time_frame>From Cycle 2 to Cycle 5 (each cycle is 28 days)</time_frame>
    <description>Minimum plasma concentration [Cmin,ss]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at single dose [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Area under the curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at single dose [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lucitanib PK Profile at single dose [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Time to maximum plasma concentration [Tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Area under the curve [AUC]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Maximum plasma concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of food (fasted or fed) on the Lucitanib PK Profile [Food Effect Cohort]</measure>
    <time_frame>From first dose of study drug to Day -1</time_frame>
    <description>Time to maximum plasma concentration [Tmax]</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">227</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1b: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Up to 50 patients with advanced solid tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b: Food Effect Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Approximately 16 evaluable patients with an advanced, metastatic solid tumor will be enrolled</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Expansion Cohort - Endometrial Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent endometrial carcinoma at least 1 prior platinum-based chemotherapy regimen&#xD;
Up to 10 patients who have progressed on treatment with 1 prior PD-(L)1 inhibitor administered as monotherapy will be allowed to enroll</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Expansion Cohort - Ovarian Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma&#xD;
At least 2 prior chemotherapy regimens which at least 1 must have been platinum-doublet chemotherapy&#xD;
Up to 10 subjects with recurrent ovarian, fallopian tube, or primary peritoneal cancer, of any histology excluding clear cell carcinoma who have progressed within 6 months after completing first-line platinum-based chemotherapy will be allowed to enroll</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Expansion Cohort - Clear Cell Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent, metastatic clear cell carcinoma of ovarian, fallopian tube, primary peritoneal or endometrial origin&#xD;
At least 1 prior platinum- and taxane-based chemotherapy regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Expansion Cohort - Cervical Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persistent or recurrent cervix cancer of squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma histology&#xD;
At least 1 prior regimen of platinum-based chemotherapy, with or without bevacizumab, for metastatic disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucitanib</intervention_name>
    <description>Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.</description>
    <arm_group_label>Phase 1b: Dose Escalation</arm_group_label>
    <other_name>CO-3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucitanib</intervention_name>
    <description>Oral lucitanib will be administered once daily (QD). The dose will be 6 mg.</description>
    <arm_group_label>Phase 1b: Food Effect Cohort</arm_group_label>
    <other_name>CO-3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucitanib</intervention_name>
    <description>Oral lucitanib will be administered once daily (QD) at the starting dose of 6 mg.&#xD;
Subjects will be allowed to intrapatient dose escalate in increments of 2 mg up to a total dose of 10 mg QD lucitanib if they meet the study specific clinical criteria.</description>
    <arm_group_label>Phase 2: Expansion Cohort - Cervical Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Clear Cell Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Endometrial Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Ovarian Cancer</arm_group_label>
    <other_name>CO-3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>IV nivolumab 480 mg will be administered once every 4 weeks.</description>
    <arm_group_label>Phase 1b: Dose Escalation</arm_group_label>
    <arm_group_label>Phase 1b: Food Effect Cohort</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Cervical Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Clear Cell Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Endometrial Cancer</arm_group_label>
    <arm_group_label>Phase 2: Expansion Cohort - Ovarian Cancer</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years of age&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
          -  Advanced/metastatic solid tumor (Phase 1b)&#xD;
&#xD;
          -  Availability of tumor tissue at screening&#xD;
&#xD;
          -  ECOG performance status of 0 to 1&#xD;
&#xD;
          -  Measurable disease (RECIST v1.1) (Phase 2)&#xD;
&#xD;
          -  Advanced, recurrent, or metastatic gynecological solid tumor (Phase 2)&#xD;
&#xD;
          -  Willing and able to fast, and to eat a high-fat breakfast (Food Effect)&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with lucitanib&#xD;
&#xD;
          -  Active second malignancy&#xD;
&#xD;
          -  Active central nervous system brain metastases&#xD;
&#xD;
          -  Pre-existing duodenal stent or any gastrointestinal disorder&#xD;
&#xD;
          -  Known history of HIV or AIDs; positive result of hepatitis B or C viruses&#xD;
&#xD;
          -  Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of&#xD;
             myocarditis&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease (eg, autoimmune hepatitis)&#xD;
&#xD;
          -  Condition requiring systemic treatment with corticosteroids or other immune&#xD;
             suppressive medications&#xD;
&#xD;
          -  Unstable or uncontrolled hypertension (BP ≥ 140/90 mmHg)&#xD;
&#xD;
          -  Prior treatment with a VEGFR-tyrosine kinase inhibitor (Phase 2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erika Hamilton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tennessee Oncology, PLLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Concin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KEM Kliniken Essen Mitte Evang. Huyssens-Stiftung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clovis Oncology For North America, Latin America and Asia Pacific inquiries:</last_name>
    <phone>1-415-409-7220, 1-844-258-7662</phone>
    <email>medinfo@clovisoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clovis Oncology For Europe and Rest of World related inquiries:</last_name>
    <phone>+353 16950030 (toll-paid)</phone>
    <email>MedInfo.IE@clovisoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Laura and Isaac Perlmutter Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Luc Univerisity Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven, Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Mannhein</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polyclinic S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute -IRCCS &quot;Fondazione G. Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Foundation IRCCS Hospital Agostino Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <state>Andalusia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Navarra University Clinic</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2019</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lucitanib</keyword>
  <keyword>nivolumab</keyword>
  <keyword>antineoplastic agents immunological</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>tyrosine kinase inhibitors</keyword>
  <keyword>gynecologic neoplasms</keyword>
  <keyword>checkpoint inhibitor</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>clear cell cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>Immuno-oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

